Asset Details
Do you wish to reserve the book?
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma
Do you wish to request the book?
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR -mutant glioblastoma
2019
Overview
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and carries a dismal prognosis. The
gene is among the most commonly deranged genes in GBM and thus an important therapeutic target. We report the case of a young female with heavily pretreated
-mutated GBM, for whom we initiated osimertinib, an oral, third-generation tyrosine kinase inhibitor that irreversibly inhibits EGFR and has significant brain penetration. We then review some of the main challenges in targeting EGFR, including lack of central nervous system penetration with most tyrosine kinase inhibitors, molecular heterogeneity of GBM and the need for enhanced specificity for the
mutations relevant in GBM.
Publisher
Future Medicine Ltd,Taylor & Francis Group
